ADC Therapeutics is a commercial stage biotechnology company headquartered in Lausanne, Switzerland, with operations in the United States. The company specializes in antibody drug conjugates, commonly called ADCs. These medicines are designed to combine the targeting ability of an antibody with a therapeutic payload. ADC Therapeutics focuses on developing ADCs for cancer, with its current strategy centered on expanding the use of ZYNLONTA and advancing selected research programs.
ADC Therapeutics develops medicines based on the concept that antibodies can identify specific proteins associated with cancer cells. An ADC generally contains an antibody, a linker, and a cytotoxic payload. The antibody helps direct the medicine toward cells carrying a particular target, while the payload is intended to produce an anticancer effect. The linker connects these components and influences how the payload is released.
The company has developed specialized capabilities covering research, clinical development, manufacturing, and commercialization. Its research approach has included different payloads, linkers, targets, and conjugation technologies. In recent years, the company has focused its resources more strongly on ZYNLONTA and selected development opportunities.
Key areas associated with its research include:
ZYNLONTA, also known as loncastuximab tesirine, is a CD19 directed antibody drug conjugate. It has received accelerated approval from the U.S. Food and Drug Administration for certain adults with relapsed or refractory large B cell lymphoma after two or more lines of systemic therapy. It has also received conditional or other regulatory approvals in several international markets.
ADC Therapeutics is studying ways to expand the use of ZYNLONTA. The company has pursued development in earlier lines of diffuse large B cell lymphoma through clinical trials such as LOTIS 5 and LOTIS 7. Research is also being conducted in certain indolent lymphomas, including follicular lymphoma and marginal zone lymphoma.
Other research areas include:
The company reported that IND enabling activities for ADCT 241, an exatecan based PSMA targeting ADC, were completed at the end of 2025, while it continues to explore partnering opportunities for the program.
ADC Therapeutics illustrates how antibody drug conjugate technology is being developed as part of modern oncology research. Its current activities emphasize ZYNLONTA, clinical development in lymphoma, international expansion, and selected next generation ADC research. As with other biotechnology programs, clinical studies and regulatory evaluations remain important for determining how investigational therapies may develop in the future. This information is provided for educational purposes and is not a substitute for professional medical advice